drugset / Trial / NCT02234843

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

NCT02234843

Phase 3 Completed 500 enrolled Bayer Janssen Research & Development, LLC · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate comparative efficacy and safety of rivaroxaban to standard of care in children with acute venous thromboembolism.

Timeline

Start
2014-11-13
Primary completion
2019-01-30
Completion
2019-01-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivaroxaban Other / unclassified 20 mg Oral